Advanced Cancer Clinical Trial
— OASISOfficial title:
Use of Telehealth Technologies for Symptom Management Support for People With Advanced Cancer Living in Rural Communities
Verified date | May 2024 |
Source | University of Iowa |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Nearly 20% of Americans and 41% of Iowans live in rural or non-metropolitan areas.(1) Lack of access to providers, long travel distances, and a disconnected health system contribute to increased distress and lower quality-of-life (QOL) in people with advanced cancer living in rural areas. (2) In the state of Iowa, 94% of rural residents have high-speed internet access. (3) The University of Iowa Health Care (UIHC) eHealth eNovation Center has developed the infrastructure to address the health care access gap in Iowa. The combination of wide availability of high-speed internet and the eHealth network provides an opportunity to develop and test interventions that leverage this infrastructure in order to address this important palliative care gap. This is a pilot study to evaluate the feasibility of an eHealth self-management intervention for cancer symptom management. The intervention consists of a web-application that provides tailored educational information about cancer symptoms and a monitoring platform to track symptom distress and strategies used to manage them. Participants will also receive e-visits from a research nurse or research assistant via UIHC eHealth and eNovation video platform. The purpose of this study is obtain feasibility data about the intervention for a future RCT and to evaluate the OASIS intervention with patients living in rural Iowa receiving treatment for advanced cancer. The specific aims are: 1. to evaluate the feasibility of the OASIS intervention to self-manage symptoms of rural patients with advanced cancer, including a) recruitment and retention, b) use patterns, c) usability of each component of the intervention (i.e., the e-visit platform and the web-application), d) acceptability of the intervention and study (i.e., satisfaction, barriers and facilitators to use, burden); and 2. to determine preliminary effects of the intervention on self-management behaviors and symptom severity, symptom distress, and symptom interference.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | September 20, 2019 |
Est. primary completion date | January 20, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: - Adults (18 yrs or older) with a current diagnosis of advanced cancer of solid tumor (stage 3 or 4) origin considered incurable by the treating oncologist, - Experiencing with at least one distressing symptoms (rated 3 or greater on 0-10 numeric rating scale for symptom distress), - Able to read and write in English - Have a laptop, mobile phone and/or tablet with a video camera that can use to access the internet - Have high-speed internet connection in his/her home Exclusion Criteria: - Patients who are not able to complete the study surveys (alone or with assistance) due impaired mental, cognitive, or physical status. |
Country | Name | City | State |
---|---|---|---|
United States | McCreery Cancer Center | Fairfield | Iowa |
Lead Sponsor | Collaborator |
---|---|
Stephanie Gilbertson-White | Icahn School of Medicine at Mount Sinai |
United States,
Connect Iowa. Broadband Infrastructure at a State and Local Level in Iowa. 2015.
Pedro LW, Schmiege SJ. Rural living as context: a study of disparities in long-term cancer survivors. Oncol Nurs Forum. 2014 May;41(3):E211-9. doi: 10.1188/14.ONF.E211-E219. — View Citation
U.S. Census Bureau. Urban, Urbanized Area, Urban Cluster, and Rural Population, 2010 and 2000: United States. 2010; https://www.census.gov. Accessed 12/23/2015.
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measuring change in Health Education Impact Questionnaire (heiQ) | An outcomes and evaluation measure for patient education and self-management interventions for people. This scale is assessing change between four time points | Week 0,4, 8, 12 | |
Primary | Measuring change in Symptom burden (MDASI - core) | Assess patient-reported symptom severity and interference in patients with cancer. This scale is assessing change between four time points | Week 0,4, 8, 12 | |
Primary | Measuring change in QOL (FACT-G) | This is a patient-reported outcome measure used to assess health-related quality of life in patients undergoing cancer therapy. This scale is assessing change between four time points. | Week 0,4,8,12 | |
Secondary | Recruitment | The number of patients approached who agree to participate | Week 0 | |
Secondary | Retention rates | The number of patients who complete measures at each time point | Week 0 | |
Secondary | Retention rates | The number of patients who complete measures at each time point | Week 4 | |
Secondary | Retention rates | The number of patients who complete measures at each time point | Week 8 | |
Secondary | Retention rates | The number of patients who complete measures at each time point | Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Completed |
NCT01901237 -
Yoga for Adolescent and Young Adult Non-Curative Cancer Patients
|
N/A | |
Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 |